Treatment with the Bv8 antagonist, PKRA7, suppressed tumor formation in vivo by inhibiting angiogenesis in GBM and infiltration of MDSCs in pancreatic cancer (96). This evidence concerns the gene PROK2 and familial pancreatic carcinoma.